Morris Arlene sold $1.7M of COGT
Morris Arlene sold 45,510 shares of Cogent Biosciences, Inc. (COGT) at an average of $37.12 ($37.09–$37.54, $1.69M total) across 2 trades on 2026-08-27 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The filing provides fresh, material information about insider sentiment, useful for short‑term trading decisions.
Market read
Direct insider sell may prompt short sellers; investors may monitor for further insider activity.
What to watch
Potential upcoming clinical data releases could offset sell pressure if positive.
Background
Form 4 filings disclose insider transactions; a director’s complete exit is noteworthy for shareholders.
Ticker impact
Director Morris Arlene sold 45,510 shares for $1.69M via a 10b5-1 plan, reducing holdings to zero.
Possible modest downside pressure in the near term.
Large director sale under a pre-arranged plan suggests personal liquidity need, but no immediate catalyst beyond the filing.
Market effects
Minimal impact on biotech sector; insider sell is company‑specific.
No broader regional effect.
Limited to investors tracking Cogent Biosciences.
Counterpoint
The sale may be purely personal liquidity; the company’s fundamentals remain unchanged.
Key entities
- CompanyCogent Biosciences, Inc.
Biotech firm developing RNA‑targeted therapeutics.
- IndividualMorris Arlene
Director of Cogent Biosciences.